

John K Ramage

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9491160/john-k-ramage-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

135 papers	8,719 citations	48 h-index	92 g-index
149 ext. papers	10,292 ext. citations	7.2 avg, IF	5.31 L-index

#	Paper	IF	Citations
135	TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 449, 395-401	5.1	1185
134	Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). <i>Gut</i> , 2012 , 61, 6-32	19.2	522
133	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. <i>Annals of Oncology</i> , 2015 , 26, 1604-20	10.3	363
132	ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016 , 103, 119-24	5.6	258
131	Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. <i>Lancet, The</i> , 1993 , 342, 391-4	4.0	255
130	Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. <i>Gut</i> , 2005 , 54 Suppl 4, iv1-16	19.2	241
129	Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. <i>Neuroendocrinology</i> , 2008 , 87, 47-62	5.6	240
128	Gastrinoma (duodenal and pancreatic). <i>Neuroendocrinology</i> , 2006 , 84, 173-82	5.6	216
127	Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. <i>Gut</i> , 2010 , 59, 1245-51	19.2	212
126	Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. <i>Gastroenterology</i> , 1995 , 108, 865-9	13.3	209
125	Well-differentiated pancreatic nonfunctioning tumors/carcinoma. <i>Neuroendocrinology</i> , 2006 , 84, 196-211	5.6	206
124	Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. <i>Endocrine-Related Cancer</i> , 2009 , 16, 885-94	5.7	202
123	Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. <i>Neuroendocrinology</i> , 2008 , 87, 8-19	5.6	198
122	Well-differentiated pancreatic tumor/carcinoma: insulinoma. <i>Neuroendocrinology</i> , 2006 , 84, 183-8	5.6	191
121	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. <i>Nature Communications</i> , 2015 , 6, 8019	17.4	185
120	The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. <i>Hepatology</i> , 2016 , 63, 930-50	11.2	184
119	Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. <i>European Journal of Cancer</i> , 2007 , 43, 1810-20	7.5	177

118	ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016 , 103, 139-43	5.6	153
117	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. <i>Neuroendocrinology</i> , 2017 , 105, 295-309	5.6	142
116	Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 5075-86	4.4	139
115	ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2017 , 105, 255-265	5.6	136
114	Well-differentiated gastric tumors/carcinomas. <i>Neuroendocrinology</i> , 2006 , 84, 158-64	5.6	113
113	Management of neuroendocrine liver metastases. <i>American Journal of Surgery</i> , 2004 , 187, 39-46	2.7	112
112	Rare functioning pancreatic endocrine tumors. <i>Neuroendocrinology</i> , 2006 , 84, 189-95	5.6	104
111	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , 2021 , 22, 690-701	21.7	100
110	Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. <i>Neuroendocrinology</i> , 2008 , 87, 20-30	5.6	95
109	Ranitidine 150 mg twice daily vs 300 mg nightly in treatment of duodenal ulcers. <i>Lancet</i> , 1984 , 2, 274-6	4.0	93
108	Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. <i>Neuroendocrinology</i> , 2008 , 87, 31-9	5.6	90
107	Nodular regenerative hyperplasia of the liver graft after liver transplantation. <i>Hepatology</i> , 1994 , 20, 88-94	11.2	88
106	Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). <i>Neuroendocrinology</i> , 2006 , 84, 212-5	5.6	86
105	Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1511-9	5.6	84
104	Clinical features, diagnosis and outcome of acute portal vein thrombosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2000 , 93, 531-4	2.7	84
103	Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 114	3	81
102	Effect of immunologic reactions on rat intestinal epithelium. <i>Gastroenterology</i> , 1988 , 94, 1368-1375	13.3	77
101	Review article: the investigation and management of gastric neuroendocrine tumours. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1071-84	6.1	72

100	Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1087-97	6.1	69
99	Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantation. <i>Gastroenterology</i> , 1994 , 107, 1425-9	13.3	69
98	Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. <i>British Journal of Cancer</i> , 2013 , 108, 301-10	8.7	68
97	Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. <i>Journal of Clinical Epidemiology</i> , 2020 , 118, 1-8	5.7	65
96	Intestinal mucosal injury is associated with mast cell activation and leukotriene generation during Nippostrongylus-induced inflammation in the rat. <i>Digestive Diseases and Sciences</i> , 1989 , 34, 724-31	4	62
95	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 626-634	18.8	60
94	Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. <i>Neuroendocrinology</i> , 2008 , 87, 40-6	5.6	60
93	Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours. <i>European Journal of Cancer</i> , 2006 , 42, 477-84	7.5	57
92	Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). <i>Neuroendocrinology</i> , 2006 , 84, 165-72	5.6	56
91	Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment. <i>Gut</i> , 1995 , 36, 142-5	19.2	55
90	ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. <i>Neuroendocrinology</i> , 2010 , 91, 341-50	5.6	51
89	Review article: the investigation and management of rectal neuroendocrine tumours. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 332-45	6.1	50
88	Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. <i>Liver Transplantation</i> , 1995 , 1, 118-21		49
87	Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. <i>British Journal of Surgery</i> , 2009 , 96, 291-8	5.3	42
86	p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. <i>Gut</i> , 1996 , 38, 265-8	19.2	41
85	Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 739-44	2.2	38
84	Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. <i>Seminars in Oncology</i> , 2018 , 45, 236-248	5.5	37
83	The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. <i>Journal of Hepatology</i> , 1997 , 27, 1015-21	13.4	36

82	Changes in intestinal permeability and epithelial differentiation during inflammation in the rat. <i>Gut</i> , 1988 , 29, 57-61	19.2	36
81	Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. <i>Clinical Therapeutics</i> , 2017 , 39, 2158-2168	3.5	32
80	Differential item functioning (DIF) in the EORTC QLQ-C30: a comparison of baseline, on-treatment and off-treatment data. <i>Quality of Life Research</i> , 2009 , 18, 381-8	3.7	29
79	Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2003 , 15, 139-43	2.2	28
78	Parvovirus B19-induced red cell aplasia treated with plasmapheresis and immunoglobulin. <i>Lancet, The</i> , 1994 , 343, 667-8	4.0	27
77	A multimodal approach to the management of neuroendocrine tumour liver metastases. <i>International Journal of Hepatology</i> , 2012 , 2012, 819193	2.7	25
76	Antigen-induced mucosal damage and restitution in the small intestine of the immunized rat. <i>International Archives of Allergy and Immunology</i> , 1990 , 91, 270-7	3.7	24
75	How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 146-52	2.2	24
74	Delays and routes to diagnosis of neuroendocrine tumours. <i>BMC Cancer</i> , 2018 , 18, 1122	4.8	23
73	Neuroendocrine Tumors. <i>Gastroenterology Clinics of North America</i> , 2016 , 45, 487-507	4.4	22
72	Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015. <i>British Journal of Cancer</i> , 2019 , 121, 966-972	8.7	21
71	Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. <i>Journal of Oncology</i> , 2020 , 2020, 8341426	4.5	21
70	Large single daily dose of histamine H2 receptor antagonist for duodenal ulcer. How much and when? A clinical pharmacological study. <i>Gut</i> , 1987 , 28, 566-72	19.2	21
69	Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. <i>British Journal of Cancer</i> , 2011 , 104, 587-92	8.7	20
68	Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. <i>BMC Cancer</i> , 2019 , 19, 66	4.8	20
67	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 951-960	6.1	20
66	Effect of immunologic reactions on rat intestinal epithelium. Correlation of increased permeability to chromium 51-labeled ethylenediaminetetraacetic acid and ovalbumin during acute inflammation and anaphylaxis. <i>Gastroenterology</i> , 1988 , 94, 1368-75	13.3	19
65	Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. <i>Clinical Therapeutics</i> , 2018 , 40, 2006-2020.e2	3.5	18

64	High-intensity interval training and moderate-intensity continuous training in adults with Crohn's disease: a pilot randomised controlled trial. <i>BMC Gastroenterology</i> , 2019 , 19, 19	3	17
63	ENETS TNM Staging Predicts Prognosis in Small Bowel Neuroendocrine Tumours. <i>ISRN Oncology</i> , 2013 , 2013, 420795		17
62	Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. <i>British Journal of Cancer</i> , 2016 , 115, 1032-1038	8.7	17
61	GLP-1 and glucagon secretion from a pancreatic neuroendocrine tumor causing diabetes and hyperinsulinemic hypoglycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3039-45	5.6	16
60	Measurement of quality of life in carcinoid/neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2003 , 10, 483-6	5.7	16
59	Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2018 , 22, 1-326	4.4	16
58	Nutritional and vitamin status in patients with neuroendocrine neoplasms. <i>World Journal of Gastroenterology</i> , 2019 , 25, 1171-1184	5.6	16
57	Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. <i>Clinical Therapeutics</i> , 2018 , 40, 952-962.e2	3.5	16
56	Presenting Symptoms and Delay in Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018 , 107, 42-49	5.6	15
55	Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan). <i>QJM - Monthly Journal of the Association of Physicians</i> , 1996 , 89, 539-42	2.7	15
54	Effect of enprostil, a synthetic prostaglandin E2 on 24 hour intragastric acidity, nocturnal acid and pepsin secretion. <i>Gut</i> , 1986 , 27, 1054-7	19.2	14
53	Ribavirin therapy for hepatitis C infection following liver transplantation. <i>Transplant International</i> , 1995 , 8, 61-4	3	14
52	Effect of cimetidine and pirenzepine in combination on 24 hour intragastric acidity in subjects with previous duodenal ulceration. <i>Gut</i> , 1986 , 27, 428-32	19.2	13
51	Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7). <i>European Journal of Cancer Care</i> , 2018 , 27, e12786	2.4	13
50	A cross-cultural convergent parallel mixed methods study of what makes a cancer-related symptom or functional health problem clinically important. <i>Psycho-Oncology</i> , 2018 , 27, 548-555	3.9	12
49	Nodular regenerative hyperplasia of the liver graft after liver transplantation. <i>Hepatology</i> , 1994 , 20, 88-94	11.2	12
48	Inhibition of food stimulated acid secretion by misoprostol, an orally active synthetic E1 analogue prostaglandin. <i>British Journal of Clinical Pharmacology</i> , 1985 , 19, 9-12	3.8	11
47	Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. <i>Neuroendocrinology</i> , 2019 , 108, 45-53	5.6	11

46	International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer. <i>Quality of Life Research</i> , 2020 , 29, 1405-1417	3.7	10
45	Overview: the management of metastatic carcinoid tumors. <i>Liver Transplantation</i> , 1995 , 1, 107-10		10
44	The European organization for research and treatment of cancer - satisfaction with cancer care questionnaire: revision and extended application development. <i>Psycho-Oncology</i> , 2017 , 26, 400-404	3.9	9
43	Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial). <i>Neuroendocrinology</i> , 2019 , 108, 317-327	5.6	9
42	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021 , 160, 2483-2495.e26	13.3	9
41	Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours. <i>Endocrine Connections</i> , 2017 , 6, 876-885	3.5	8
40	Carcinoid syndrome. <i>BMJ, The</i> , 2010 , 341, c3941	5.9	7
39	Neuroendocrine tumour management: a team approach. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005 , 66, 37-42	0.8	7
38	Churg-Strauss syndrome and granulomatous cholangiopathy. <i>European Journal of Gastroenterology and Hepatology</i> , 2000 , 12, 809-11	2.2	7
37	Barrett's oesophagus. <i>Lancet, The</i> , 1987 , 2, 851	4.0	7
36	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≥ 1 cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020 , 7, 598438	4.9	7
35	Thresholds for clinical importance were defined for the European Organisation for Research and Treatment of Cancer Computer Adaptive Testing Core-an adaptive measure of core quality of life domains in oncology clinical practice and research. <i>Journal of Clinical Epidemiology</i> , 2020 , 117, 117-125	5.7	7
34	Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme. <i>Colorectal Disease</i> , 2018 , 20, O85-O91	2.1	6
33	Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. <i>World Journal of Gastroenterology</i> , 2020 , 26, 3686-3711	5.6	6
32	Optimized Outcomes Using a Standardized Approach for the Treatment of Patients with Carcinoid Heart Disease. <i>Neuroendocrinology</i> , 2017 , 104, 257-263	5.6	5
31	Are renal microgranulomas related to inflammatory tubular destruction?. <i>Journal of Clinical Pathology</i> , 2004 , 57, 551-2	3.9	5
30	FK 506 rescue therapy for intractable liver allograft rejection. <i>Transplant International</i> , 1994 , 7 Suppl 1, S70-6	3	5
29	Affective and enjoyment responses to 12 weeks of high intensity interval training and moderate continuous training in adults with Crohn's disease. <i>PLoS ONE</i> , 2019 , 14, e0222060	3.7	4

28	A Systematic Review of Symptoms and Quality of Life Issues in Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2017 , 105, 320-330	5.6	4
27	Effect of region, temperature and neuronal blockade on sodium and ⁵¹ Cr-EDTA transport across canine gastrointestinal mucosae in vitro. <i>Comparative Biochemistry and Physiology A, Comparative Physiology</i> , 1994 , 107, 711-7		4
26	Health-related quality of life in neuroendocrine neoplasia: a critical review. <i>Endocrine-Related Cancer</i> , 2020 , 27, R267-R280	5.7	4
25	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors.. <i>Journal of Neuroendocrinology</i> , 2022 , e13105	3.8	4
24	Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. <i>Anti-Cancer Drugs</i> , 2020 , 31, 216-222	2.4	3
23	Smoking, gastric secretion, and inhibition by H2 receptor antagonists. <i>Lancet, The</i> , 1985 , 1, 1049	4.0	3
22	Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment. <i>Journal of Palliative Medicine</i> , 2021 , 24, 397-404	2.2	3
21	Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome. A single-centre study from a centre of excellence. <i>Nuclear Medicine Communications</i> , 2020 , 41, 575-581	1.6	2
20	Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?. <i>International Journal of Endocrine Oncology</i> , 2015 , 2, 201-215	0.3	1
19	A treatable cause of lymphocytic meningo-encephalitis. <i>Postgraduate Medical Journal</i> , 1997 , 73, 437-8	2	1
18	Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours.. <i>Journal of Neuroendocrinology</i> , 2022 , e13096	3.8	1
17	Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 64	2.6	1
16	Efficacy and safety of ¹⁷⁷ Lu-DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): Data from the NETTER-R international, retrospective registry.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4116-4116	2.2	1
15	The Impact of Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. <i>Frontiers in Endocrinology</i> , 2021 , 12, 654975	5.7	1
14	Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply. <i>Lancet Oncology, The</i> , 2021 , 22, e288-e289	21.7	1
13	Efficacy and safety of Lu-DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 , 1	8.8	1
12	Evaluating cost-effectiveness in the management of neuroendocrine neoplasms. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 647-663	10.5	0
11	Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module).. <i>Journal of Neuroendocrinology</i> , 2022 , e13097	3.8	0

10	Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire.. <i>Journal of Cancer Survivorship</i> , 2022 , 1	5.1	o
9	Nodal metastases in small rectal neuroendocrine tumours. <i>Colorectal Disease</i> , 2021 , 23, 3173	2.1	o
8	Calcitonin-secreting neuroendocrine neoplasms of the lung: a systematic review and narrative synthesis. <i>Endocrine Connections</i> , 2021 , 10, 447-461	3.5	o
7	Finding the needle in the haystack: the diagnostic accuracy of the faecal immunochemical test for colorectal cancer in younger symptomatic patients. <i>Colorectal Disease</i> , 2021 , 23, 2539-2549	2.1	o
6	Tumour Staging: Ileum 2018 , 197-206		
5	Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by Ki67 score--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 1034-5	6.1	
4	Reply to the Letter by Scherübl on Well-Differentiated Neuroendocrine Tumours of Colon and Rectum. <i>Neuroendocrinology</i> , 2008 , 88, 158-159	5.6	
3	Tumeurs carcinoïdes de l'intestin grêle. <i>Acta Endoscopica</i> , 2005 , 35, 187-193		
2	Acute diarrhoea in expatriates in Bangladesh. <i>Gut</i> , 1990 , 31, 123	19.2	
1	Acute Liver Failure in a Patient Travelling From Asia: The Other Face of the Coin of Infectious Disease. <i>Gastroenterology Research</i> , 2017 , 10, 268-270	1.8	